Quick Nav
Publications
Pharmacy Times
GI Watch

Renzapride Accelerates Colonic Transit in IBS-C Patients

Published Online: Wednesday, December 1, 2004   [ Request Print ]

The pathophysiology of irritable bowel syndrome (IBS) is thought to be multifactorial, and physical and psychosocial factors may contribute to overall symptom presentation. Therapies that target these contributing factors have been developed.

Renzapride is a serotonin type 4 receptor agonist/type 3 receptor antagonist. The effect of this agent on colonic transit (CT) in patients with IBS with constipation (IBS-C; n = 48, of whom 46 were women) was examined. The findings of this study were published in the October 2004 issue of Clinical Gastroenterology and Hepatology.

Results demonstrated a linear dose response to renzapride for CT and ascending colon emptying, but not for gastric emptying or small bowel transit. The median ascending colon half-time transit was 5.0 hours in patients treated with 4 mg renzapride (n = 12), compared with 17.5 hours in those in the placebo group (n = 12). Improved bowel function scores (ie, stool form, ease of passage) were significantly (P < .05) associated with accelerated CT. The authors concluded that renzapride causes clinically significant CT acceleration, which is associated with bowel function improvement in women with IBS-C.

Related Articles
No Result Found




Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-257-0701

Copyright HCPLive 2006-2013
Intellisphere, LLC. All Rights Reserved.
 




Become a Member
Forgot Password?